195 related articles for article (PubMed ID: 30676812)
1. Efficacy of iguratimod
Nozaki Y; Inoue A; Kinoshita K; Funauchi M; Matsumura I
Mod Rheumatol; 2020 Mar; 30(2):249-258. PubMed ID: 30676812
[No Abstract] [Full Text] [Related]
2. Iguratimod versus salazosulfapyridine in rheumatoid arthritis patients with an inadequate response to methotrexate: Adjusted with propensity score matching.
Nozaki Y; Oribe M; Tomita D; Itami T; Hayashi S; Maeda T; Fukuda K; Kuroda R; Funahashi K; Matsubara T; Kinoshita K; Matsumura I
Mod Rheumatol; 2023 Apr; 33(3):472-480. PubMed ID: 35695707
[TBL] [Abstract][Full Text] [Related]
3. The add-on effectiveness and safety of iguratimod in patients with rheumatoid arthritis who showed an inadequate response to tocilizumab.
Ebina K; Miyama A; Tsuboi H; Kaneshiro S; Nishikawa M; Owaki H; Tsuji S; Hirao M; Etani Y; Goshima A; Hashimoto J; Yoshikawa H
Mod Rheumatol; 2019 Jul; 29(4):581-588. PubMed ID: 29882440
[No Abstract] [Full Text] [Related]
4. The three-year efficacy of iguratimod in clinical daily practice in patients with rheumatoid arthritis.
Suto T; Yonemoto Y; Okamura K; Sakane H; Takeuchi K; Tamura Y; Kaneko T; Ayabe K; Chikuda H
Mod Rheumatol; 2019 Sep; 29(5):775-781. PubMed ID: 30092680
[No Abstract] [Full Text] [Related]
5. [DMARDs (Focusing on iguratimod)].
Ito S
Nihon Rinsho; 2016 Jun; 74(6):948-54. PubMed ID: 27311184
[TBL] [Abstract][Full Text] [Related]
6. Iguratimod, a synthetic disease modifying anti-rheumatic drug inhibiting the activation of NF-κB and production of RANKL: Its efficacy, radiographic changes, safety and predictors over two years' treatment for Japanese rheumatoid arthritis patients.
Ishikawa K; Ishikawa J
Mod Rheumatol; 2019 May; 29(3):418-429. PubMed ID: 29798702
[TBL] [Abstract][Full Text] [Related]
7. Genetic predictors of efficacy and toxicity of iguratimod in patients with rheumatoid arthritis.
Xiao W; Guo JP; Li C; Ye H; Wei W; Zou Y; Dai L; Li Z; Zhang M; Li X; Cai X; Zhao J; Wang Y; Tao Y; Liu D; Li Y; Wu M; Sun E; Wu L; Luo L; Mu R; Li Z
Pharmacogenomics; 2018 Apr; 19(5):383-392. PubMed ID: 29517409
[TBL] [Abstract][Full Text] [Related]
8. Iguratimod for the treatment of rheumatoid arthritis in Japan.
Tanaka K; Yamaguchi T; Hara M
Expert Rev Clin Immunol; 2015 May; 11(5):565-73. PubMed ID: 25797025
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis: a controlled, multicenter, double-blind, parallel-group study.
Hara M; Abe T; Sugawara S; Mizushima Y; Hoshi K; Irimajiri S; Hashimoto H; Yoshino S; Matsui N; Nobunaga M; Nakano S
Mod Rheumatol; 2007; 17(1):1-9. PubMed ID: 17278015
[TBL] [Abstract][Full Text] [Related]
10. Safety and effectiveness of 24-week treatment with iguratimod, a new oral disease-modifying antirheumatic drug, for patients with rheumatoid arthritis: interim analysis of a post-marketing surveillance study of 2679 patients in Japan.
Mimori T; Harigai M; Atsumi T; Fujii T; Kuwana M; Matsuno H; Momohara S; Takei S; Tamura N; Takasaki Y; Ikeuchi S; Kushimoto S; Koike T
Mod Rheumatol; 2017 Sep; 27(5):755-765. PubMed ID: 27919207
[TBL] [Abstract][Full Text] [Related]
11. Safety and effectiveness of iguratimod in patients with rheumatoid arthritis: Final report of a 52-week, multicenter postmarketing surveillance study.
Mimori T; Harigai M; Atsumi T; Fujii T; Kuwana M; Matsuno H; Momohara S; Takei S; Tamura N; Takasaki Y; Yamamoto K; Ikeuchi S; Kushimoto S; Koike T
Mod Rheumatol; 2019 Mar; 29(2):314-323. PubMed ID: 29611761
[TBL] [Abstract][Full Text] [Related]
12. Clinical effectiveness of iguratimod based on real-world data of patients with rheumatoid arthritis.
Mizutani S; Kodera H; Sato Y; Nanki T; Yoshida S; Yasuoka H
Clin Rheumatol; 2021 Jan; 40(1):123-132. PubMed ID: 32506311
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of add-on iguratimod in patients with rheumatoid arthritis who inadequately respond to either tocilizumab or tumor necrosis factor alpha inhibitors.
Hattori K; Hirano Y; Kanayama Y; Hattori Y; Kato T; Takahashi N; Ishiguro N; Kojima T
Mod Rheumatol; 2021 Jan; 31(1):80-87. PubMed ID: 32148143
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of the clinical use of iguratimod therapy in patients with rheumatoid arthritis.
Okamura K; Yonemoto Y; Okura C; Kobayashi T; Takagishi K
Mod Rheumatol; 2015 Mar; 25(2):235-40. PubMed ID: 25065917
[TBL] [Abstract][Full Text] [Related]
15. Add-on iguratimod as a therapeutic strategy to achieve remission in patients with rheumatoid arthritis inadequately responding to biological DMARDs: A retrospective study.
Yoshikawa A; Yoshida S; Kimura Y; Tokai N; Fujiki Y; Kotani T; Matsumura Y; Takeuchi T; Makino S
Mod Rheumatol; 2018 Mar; 28(2):227-234. PubMed ID: 28644744
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of iguratimod as monotherapy or combined therapy in patients with rheumatoid arthritis: a systematic review and meta-analysis of RCTs.
Hu CJ; Zhang L; Zhou S; Jiang N; Zhao JL; Wang Q; Tian XP; Zeng XF
J Orthop Surg Res; 2021 Jul; 16(1):457. PubMed ID: 34271950
[TBL] [Abstract][Full Text] [Related]
17. Relative efficacy and safety of iguratimod monotherapy for the treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis.
Shrestha S; Zhao J; Yang C; Zhang J
Clin Rheumatol; 2020 Jul; 39(7):2139-2150. PubMed ID: 32076916
[TBL] [Abstract][Full Text] [Related]
18. Molecular mechanisms and clinical application of Iguratimod: A review.
Jiang H; Gao H; Wang Q; Wang M; Wu B
Biomed Pharmacother; 2020 Feb; 122():109704. PubMed ID: 31918275
[TBL] [Abstract][Full Text] [Related]
19. Factors influencing physician decisions to discontinue treatment after onset of liver dysfunction:
Ishiguro N; Shibata K; Yoshimura A; Ikeuchi S; Ishii M
Mod Rheumatol; 2020 Jul; 30(4):633-639. PubMed ID: 31403345
[No Abstract] [Full Text] [Related]
20. Iguratimod attenuates general disease activity and improves lung function in rheumatoid arthritis-associated interstitial lung disease patients.
Shu P; Shao SQ; Cai XN; Zhou DM; Ma H; Lu L; Yin HQ; Yin SL
Eur Rev Med Pharmacol Sci; 2021 Jul; 25(14):4687-4692. PubMed ID: 34337716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
